Concepts (269)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neoplasm Recurrence, Local | 3 | 2021 | 133 | 1.630 |
Why?
|
| Anti-Bacterial Agents | 3 | 2021 | 355 | 1.250 |
Why?
|
| Genital Neoplasms, Female | 3 | 2021 | 10 | 1.190 |
Why?
|
| Cystadenocarcinoma, Serous | 2 | 2017 | 33 | 1.190 |
Why?
|
| Uterine Neoplasms | 2 | 2017 | 36 | 1.130 |
Why?
|
| Endometrial Neoplasms | 4 | 2021 | 64 | 0.990 |
Why?
|
| Carcinoma, Endometrioid | 3 | 2021 | 17 | 0.890 |
Why?
|
| Infertility | 1 | 2022 | 17 | 0.850 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2020 | 15 | 0.770 |
Why?
|
| Ovarian Neoplasms | 2 | 2022 | 303 | 0.760 |
Why?
|
| Community-Based Participatory Research | 6 | 2024 | 292 | 0.730 |
Why?
|
| Community Health Services | 4 | 2017 | 175 | 0.720 |
Why?
|
| Residence Characteristics | 3 | 2018 | 301 | 0.710 |
Why?
|
| Violence | 2 | 2018 | 126 | 0.700 |
Why?
|
| Aged | 23 | 2024 | 6448 | 0.680 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 178 | 0.680 |
Why?
|
| Humans | 50 | 2024 | 34853 | 0.640 |
Why?
|
| Female | 34 | 2022 | 19873 | 0.640 |
Why?
|
| Middle Aged | 27 | 2023 | 9642 | 0.630 |
Why?
|
| Poverty | 3 | 2016 | 316 | 0.630 |
Why?
|
| Neoplasm Staging | 7 | 2022 | 269 | 0.600 |
Why?
|
| Renal Insufficiency, Chronic | 4 | 2019 | 160 | 0.580 |
Why?
|
| Community-Institutional Relations | 3 | 2017 | 171 | 0.570 |
Why?
|
| Medically Uninsured | 2 | 2016 | 49 | 0.570 |
Why?
|
| Albuminuria | 2 | 2012 | 76 | 0.500 |
Why?
|
| Myometrium | 1 | 2014 | 12 | 0.490 |
Why?
|
| Multilingualism | 1 | 2014 | 31 | 0.480 |
Why?
|
| Urban Health Services | 1 | 2014 | 35 | 0.480 |
Why?
|
| Lymph Nodes | 1 | 2014 | 67 | 0.480 |
Why?
|
| Neoplasms | 5 | 2015 | 1033 | 0.470 |
Why?
|
| Breast Neoplasms | 4 | 2015 | 1426 | 0.450 |
Why?
|
| Cooperative Behavior | 3 | 2014 | 205 | 0.440 |
Why?
|
| Retrospective Studies | 6 | 2022 | 1961 | 0.440 |
Why?
|
| SEER Program | 3 | 2017 | 87 | 0.420 |
Why?
|
| Los Angeles | 9 | 2023 | 368 | 0.410 |
Why?
|
| Health Knowledge, Attitudes, Practice | 6 | 2015 | 790 | 0.390 |
Why?
|
| Adult | 22 | 2022 | 11034 | 0.380 |
Why?
|
| Survival Rate | 4 | 2021 | 310 | 0.380 |
Why?
|
| Kidney Failure, Chronic | 1 | 2012 | 231 | 0.380 |
Why?
|
| Health Status Disparities | 4 | 2015 | 583 | 0.360 |
Why?
|
| Mass Screening | 1 | 2012 | 427 | 0.340 |
Why?
|
| Organizational Case Studies | 1 | 2008 | 29 | 0.330 |
Why?
|
| Cohort Studies | 4 | 2022 | 1422 | 0.330 |
Why?
|
| Male | 25 | 2022 | 18870 | 0.310 |
Why?
|
| Quality of Health Care | 1 | 2008 | 136 | 0.300 |
Why?
|
| Patient Care Management | 1 | 2006 | 6 | 0.300 |
Why?
|
| Social Welfare | 1 | 2006 | 30 | 0.290 |
Why?
|
| Interdisciplinary Communication | 1 | 2006 | 34 | 0.290 |
Why?
|
| Models, Cardiovascular | 1 | 2007 | 53 | 0.290 |
Why?
|
| Early Detection of Cancer | 3 | 2020 | 292 | 0.290 |
Why?
|
| Long-Term Care | 2 | 2022 | 43 | 0.280 |
Why?
|
| Health Education | 1 | 2008 | 304 | 0.260 |
Why?
|
| Prognosis | 6 | 2022 | 707 | 0.260 |
Why?
|
| Young Adult | 8 | 2020 | 4012 | 0.260 |
Why?
|
| Medicaid | 2 | 2007 | 102 | 0.250 |
Why?
|
| Clinical Medicine | 1 | 2004 | 4 | 0.250 |
Why?
|
| Health Services | 1 | 2004 | 53 | 0.250 |
Why?
|
| Neoadjuvant Therapy | 2 | 2020 | 17 | 0.240 |
Why?
|
| Health Services Research | 1 | 2004 | 133 | 0.230 |
Why?
|
| Risk Assessment | 5 | 2021 | 727 | 0.220 |
Why?
|
| Proportional Hazards Models | 3 | 2021 | 423 | 0.220 |
Why?
|
| Cross-Sectional Studies | 6 | 2023 | 2561 | 0.220 |
Why?
|
| Lymphatic Metastasis | 3 | 2022 | 63 | 0.220 |
Why?
|
| Adolescent | 9 | 2020 | 5035 | 0.220 |
Why?
|
| Alopecia | 1 | 2022 | 9 | 0.220 |
Why?
|
| Disinfection | 1 | 2022 | 8 | 0.210 |
Why?
|
| Infection Control | 1 | 2022 | 13 | 0.210 |
Why?
|
| Cross Infection | 1 | 2022 | 38 | 0.210 |
Why?
|
| Diabetes Mellitus | 2 | 2019 | 465 | 0.210 |
Why?
|
| Insurance Coverage | 2 | 2016 | 99 | 0.200 |
Why?
|
| Vaccines | 1 | 2022 | 49 | 0.200 |
Why?
|
| Cardiovascular Diseases | 2 | 2007 | 628 | 0.200 |
Why?
|
| Incidence | 2 | 2022 | 882 | 0.200 |
Why?
|
| Aged, 80 and over | 7 | 2017 | 2333 | 0.190 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2020 | 36 | 0.190 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2020 | 18 | 0.190 |
Why?
|
| DNA Mismatch Repair | 1 | 2020 | 24 | 0.190 |
Why?
|
| Drug Interactions | 1 | 2021 | 137 | 0.190 |
Why?
|
| Cyclophosphamide | 1 | 2020 | 52 | 0.190 |
Why?
|
| Models, Statistical | 1 | 2021 | 171 | 0.190 |
Why?
|
| Cisplatin | 1 | 2020 | 70 | 0.190 |
Why?
|
| Comprehensive Health Care | 1 | 2019 | 8 | 0.180 |
Why?
|
| Medical Record Linkage | 1 | 2019 | 15 | 0.180 |
Why?
|
| United States | 6 | 2019 | 3894 | 0.180 |
Why?
|
| Postoperative Complications | 1 | 2021 | 206 | 0.180 |
Why?
|
| Health Personnel | 1 | 2022 | 200 | 0.180 |
Why?
|
| Telemedicine | 1 | 2023 | 163 | 0.180 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2007 | 592 | 0.180 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2019 | 10 | 0.180 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 964 | 0.180 |
Why?
|
| Antibodies, Protozoan | 1 | 2020 | 77 | 0.180 |
Why?
|
| Electronic Health Records | 1 | 2019 | 65 | 0.170 |
Why?
|
| Chagas Disease | 1 | 2020 | 96 | 0.170 |
Why?
|
| Midwestern United States | 1 | 2018 | 19 | 0.170 |
Why?
|
| Patient Selection | 2 | 2021 | 154 | 0.170 |
Why?
|
| Mental Disorders | 1 | 2022 | 285 | 0.170 |
Why?
|
| Risk | 2 | 2021 | 256 | 0.170 |
Why?
|
| Developing Countries | 2 | 2009 | 97 | 0.170 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2019 | 248 | 0.160 |
Why?
|
| Neoplasm Invasiveness | 2 | 2020 | 247 | 0.160 |
Why?
|
| Allostasis | 1 | 2017 | 10 | 0.150 |
Why?
|
| Qualitative Research | 2 | 2017 | 393 | 0.150 |
Why?
|
| Attitude of Health Personnel | 1 | 2019 | 186 | 0.150 |
Why?
|
| Sex Factors | 2 | 2018 | 859 | 0.150 |
Why?
|
| Pregnancy | 1 | 2022 | 1503 | 0.150 |
Why?
|
| Religion | 1 | 2017 | 77 | 0.150 |
Why?
|
| Social Class | 2 | 2016 | 228 | 0.140 |
Why?
|
| Chicago | 1 | 2016 | 24 | 0.140 |
Why?
|
| Perception | 2 | 2015 | 183 | 0.140 |
Why?
|
| Mortality | 1 | 2017 | 150 | 0.140 |
Why?
|
| Vulnerable Populations | 1 | 2017 | 132 | 0.140 |
Why?
|
| Research Subjects | 1 | 2015 | 31 | 0.130 |
Why?
|
| Healthcare Disparities | 3 | 2015 | 446 | 0.130 |
Why?
|
| Pitch Discrimination | 1 | 2014 | 1 | 0.130 |
Why?
|
| Voice | 1 | 2014 | 4 | 0.130 |
Why?
|
| Health Behavior | 3 | 2015 | 491 | 0.120 |
Why?
|
| Delphi Technique | 1 | 2014 | 22 | 0.120 |
Why?
|
| Feedback, Physiological | 1 | 2014 | 28 | 0.120 |
Why?
|
| Trust | 1 | 2015 | 119 | 0.120 |
Why?
|
| Clinical Trials as Topic | 1 | 2015 | 195 | 0.120 |
Why?
|
| Tumor Burden | 1 | 2014 | 79 | 0.120 |
Why?
|
| Risk Factors | 5 | 2020 | 3414 | 0.120 |
Why?
|
| Models, Neurological | 1 | 2014 | 123 | 0.110 |
Why?
|
| Language | 1 | 2014 | 143 | 0.110 |
Why?
|
| HIV Infections | 1 | 2006 | 2207 | 0.110 |
Why?
|
| Health Status | 1 | 2016 | 356 | 0.110 |
Why?
|
| Registries | 3 | 2020 | 330 | 0.110 |
Why?
|
| Program Development | 1 | 2014 | 225 | 0.110 |
Why?
|
| Age Factors | 4 | 2020 | 1007 | 0.110 |
Why?
|
| Cerebral Cortex | 1 | 2014 | 274 | 0.110 |
Why?
|
| Chronic Disease | 3 | 2016 | 469 | 0.110 |
Why?
|
| Nutrition Assessment | 1 | 2012 | 77 | 0.100 |
Why?
|
| Time Factors | 1 | 2016 | 1681 | 0.100 |
Why?
|
| Acupuncture Therapy | 1 | 2011 | 13 | 0.100 |
Why?
|
| Health Promotion | 1 | 2017 | 588 | 0.100 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2010 | 14 | 0.100 |
Why?
|
| Feeding Behavior | 2 | 2012 | 418 | 0.100 |
Why?
|
| Fatigue | 1 | 2011 | 79 | 0.100 |
Why?
|
| Internet | 1 | 2012 | 204 | 0.100 |
Why?
|
| Universities | 1 | 2014 | 363 | 0.100 |
Why?
|
| Hypertension | 3 | 2019 | 770 | 0.100 |
Why?
|
| Quality of Life | 1 | 2014 | 459 | 0.090 |
Why?
|
| Self Care | 1 | 2011 | 150 | 0.090 |
Why?
|
| Patient Education as Topic | 1 | 2011 | 207 | 0.090 |
Why?
|
| Biomedical Research | 1 | 2014 | 371 | 0.090 |
Why?
|
| Snake Bites | 1 | 2009 | 1 | 0.090 |
Why?
|
| Zoonoses | 1 | 2009 | 19 | 0.090 |
Why?
|
| Leptospirosis | 1 | 2009 | 26 | 0.080 |
Why?
|
| Case Management | 1 | 2008 | 21 | 0.080 |
Why?
|
| Creatinine | 1 | 2008 | 101 | 0.080 |
Why?
|
| Consensus | 1 | 2008 | 41 | 0.080 |
Why?
|
| Socioeconomic Factors | 4 | 2015 | 1003 | 0.080 |
Why?
|
| Health Surveys | 2 | 2008 | 358 | 0.080 |
Why?
|
| Stress, Psychological | 1 | 2014 | 541 | 0.080 |
Why?
|
| Education | 1 | 2008 | 48 | 0.080 |
Why?
|
| Food Supply | 1 | 2008 | 99 | 0.070 |
Why?
|
| Feasibility Studies | 2 | 2021 | 196 | 0.070 |
Why?
|
| Insurance, Health | 1 | 2007 | 120 | 0.070 |
Why?
|
| Body Mass Index | 3 | 2015 | 775 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2020 | 233 | 0.060 |
Why?
|
| Cadherins | 1 | 2005 | 82 | 0.060 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2006 | 214 | 0.060 |
Why?
|
| Capital Financing | 1 | 2004 | 2 | 0.060 |
Why?
|
| Fellowships and Scholarships | 1 | 2004 | 26 | 0.060 |
Why?
|
| Gene Deletion | 1 | 2005 | 156 | 0.060 |
Why?
|
| Internal Medicine | 1 | 2004 | 25 | 0.060 |
Why?
|
| Education, Medical, Continuing | 1 | 2004 | 31 | 0.060 |
Why?
|
| Antihypertensive Agents | 1 | 2007 | 284 | 0.060 |
Why?
|
| Public Health | 1 | 2008 | 348 | 0.060 |
Why?
|
| Prevalence | 3 | 2019 | 1425 | 0.060 |
Why?
|
| Teaching | 1 | 2004 | 51 | 0.060 |
Why?
|
| Forecasting | 1 | 2004 | 124 | 0.060 |
Why?
|
| Child | 2 | 2022 | 2875 | 0.060 |
Why?
|
| Stomach Neoplasms | 1 | 2005 | 192 | 0.060 |
Why?
|
| San Francisco | 1 | 2022 | 33 | 0.050 |
Why?
|
| Neoplasm, Residual | 1 | 2022 | 13 | 0.050 |
Why?
|
| Patients' Rooms | 1 | 2022 | 1 | 0.050 |
Why?
|
| Fomites | 1 | 2022 | 2 | 0.050 |
Why?
|
| Disinfectants | 1 | 2022 | 7 | 0.050 |
Why?
|
| Health Facilities | 1 | 2022 | 23 | 0.050 |
Why?
|
| Prostatic Neoplasms | 1 | 2010 | 794 | 0.050 |
Why?
|
| New York | 1 | 2022 | 69 | 0.050 |
Why?
|
| Ultraviolet Rays | 1 | 2022 | 116 | 0.050 |
Why?
|
| Risk-Taking | 2 | 2015 | 435 | 0.050 |
Why?
|
| Adenosine Triphosphate | 1 | 2022 | 180 | 0.050 |
Why?
|
| Hysterectomy | 1 | 2020 | 29 | 0.050 |
Why?
|
| Databases, Factual | 1 | 2021 | 288 | 0.050 |
Why?
|
| Bolivia | 1 | 2020 | 9 | 0.050 |
Why?
|
| RNA, Viral | 1 | 2022 | 287 | 0.050 |
Why?
|
| Vaccination | 1 | 2022 | 259 | 0.050 |
Why?
|
| Patient Care Team | 1 | 2020 | 44 | 0.050 |
Why?
|
| Seroepidemiologic Studies | 1 | 2020 | 67 | 0.050 |
Why?
|
| Endometrium | 1 | 2020 | 57 | 0.050 |
Why?
|
| Lymph Node Excision | 1 | 2019 | 25 | 0.040 |
Why?
|
| Gynecology | 1 | 2019 | 31 | 0.040 |
Why?
|
| Brazil | 2 | 2009 | 66 | 0.040 |
Why?
|
| Causality | 2 | 2009 | 45 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2021 | 608 | 0.040 |
Why?
|
| Mental Health | 1 | 2022 | 270 | 0.040 |
Why?
|
| Trypanosoma cruzi | 1 | 2020 | 144 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2020 | 445 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 901 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 1 | 2020 | 484 | 0.040 |
Why?
|
| Rural Population | 1 | 2020 | 253 | 0.040 |
Why?
|
| DNA Methylation | 1 | 2020 | 301 | 0.040 |
Why?
|
| Disease Progression | 1 | 2019 | 580 | 0.040 |
Why?
|
| Evidence-Based Medicine | 1 | 2017 | 92 | 0.040 |
Why?
|
| Infant | 1 | 2020 | 1014 | 0.040 |
Why?
|
| Prospective Studies | 1 | 2020 | 1353 | 0.040 |
Why?
|
| Comorbidity | 2 | 2009 | 606 | 0.040 |
Why?
|
| Cause of Death | 1 | 2017 | 154 | 0.040 |
Why?
|
| Environment Design | 1 | 2016 | 24 | 0.030 |
Why?
|
| Mutation | 1 | 2020 | 1023 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2020 | 1318 | 0.030 |
Why?
|
| Community Health Centers | 1 | 2016 | 45 | 0.030 |
Why?
|
| Marketing of Health Services | 1 | 2015 | 7 | 0.030 |
Why?
|
| Diet | 2 | 2012 | 747 | 0.030 |
Why?
|
| Information Dissemination | 1 | 2015 | 58 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2015 | 110 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2009 | 1349 | 0.030 |
Why?
|
| Pitch Perception | 1 | 2014 | 2 | 0.030 |
Why?
|
| Temporal Lobe | 1 | 2014 | 22 | 0.030 |
Why?
|
| Motor Cortex | 1 | 2014 | 20 | 0.030 |
Why?
|
| Algorithms | 1 | 2017 | 435 | 0.030 |
Why?
|
| Nerve Net | 1 | 2014 | 72 | 0.030 |
Why?
|
| Brain Mapping | 1 | 2014 | 108 | 0.030 |
Why?
|
| Prefrontal Cortex | 1 | 2014 | 133 | 0.030 |
Why?
|
| Guidelines as Topic | 1 | 2012 | 50 | 0.030 |
Why?
|
| Relaxation Therapy | 1 | 2011 | 4 | 0.030 |
Why?
|
| Integrative Medicine | 1 | 2011 | 5 | 0.030 |
Why?
|
| Evaluation Studies as Topic | 1 | 2011 | 51 | 0.030 |
Why?
|
| Focus Groups | 1 | 2012 | 307 | 0.030 |
Why?
|
| Photic Stimulation | 1 | 2011 | 109 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2014 | 468 | 0.020 |
Why?
|
| Castration | 1 | 2010 | 33 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2012 | 202 | 0.020 |
Why?
|
| Austria | 1 | 2010 | 4 | 0.020 |
Why?
|
| Physicians | 1 | 2012 | 148 | 0.020 |
Why?
|
| Colorectal Neoplasms | 1 | 2015 | 413 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2012 | 628 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2010 | 211 | 0.020 |
Why?
|
| Bothrops | 1 | 2009 | 1 | 0.020 |
Why?
|
| Crotalus | 1 | 2009 | 1 | 0.020 |
Why?
|
| Antivenins | 1 | 2009 | 2 | 0.020 |
Why?
|
| Penicillins | 1 | 2009 | 12 | 0.020 |
Why?
|
| Cognition Disorders | 1 | 2011 | 233 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2010 | 356 | 0.020 |
Why?
|
| Doxycycline | 1 | 2009 | 30 | 0.020 |
Why?
|
| Rodentia | 1 | 2009 | 41 | 0.020 |
Why?
|
| Social Support | 1 | 2011 | 356 | 0.020 |
Why?
|
| Immunologic Factors | 1 | 2009 | 44 | 0.020 |
Why?
|
| Urban Health | 1 | 2009 | 86 | 0.020 |
Why?
|
| Poverty Areas | 1 | 2008 | 37 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 2008 | 73 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2009 | 187 | 0.020 |
Why?
|
| Drug Costs | 1 | 2007 | 28 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2008 | 429 | 0.020 |
Why?
|
| Exercise | 1 | 2011 | 524 | 0.020 |
Why?
|
| Reference Values | 1 | 2006 | 204 | 0.020 |
Why?
|
| Nutrition Surveys | 1 | 2007 | 228 | 0.020 |
Why?
|
| Medicare | 1 | 2007 | 188 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2007 | 517 | 0.020 |
Why?
|
| Carbohydrate Dehydrogenases | 1 | 2005 | 14 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2006 | 570 | 0.020 |
Why?
|
| Kidney Diseases | 1 | 2006 | 159 | 0.020 |
Why?
|
| Mexico | 1 | 2005 | 223 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2005 | 322 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2005 | 859 | 0.010 |
Why?
|
| Animals | 2 | 2009 | 14307 | 0.010 |
Why?
|